Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Up – Should You Buy?

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) gapped up before the market opened on Thursday . The stock had previously closed at $12.72, but opened at $13.84. Bicara Therapeutics shares last traded at $12.96, with a volume of 26,795 shares trading hands.

Wall Street Analyst Weigh In

BCAX has been the topic of several research analyst reports. RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. HC Wainwright increased their price objective on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, January 27th. Wedbush assumed coverage on shares of Bicara Therapeutics in a research note on Thursday. They issued an “outperform” rating and a $31.00 target price for the company. Finally, Rodman & Renshaw assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price objective for the company. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $41.20.

Bicara Therapeutics Stock Performance

The firm’s 50-day moving average is $15.84.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($1.14). Equities research analysts expect that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Institutional Investors Weigh In On Bicara Therapeutics

A number of hedge funds have recently modified their holdings of the business. Spire Wealth Management acquired a new position in shares of Bicara Therapeutics in the 4th quarter valued at approximately $31,000. SG Americas Securities LLC acquired a new stake in Bicara Therapeutics during the 4th quarter worth approximately $147,000. Cinctive Capital Management LP acquired a new position in shares of Bicara Therapeutics in the third quarter valued at approximately $229,000. Barclays PLC bought a new stake in shares of Bicara Therapeutics during the third quarter worth $255,000. Finally, Jane Street Group LLC acquired a new stake in shares of Bicara Therapeutics during the third quarter worth $309,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.